Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease*

References

• Chronic Obstructive Pulmonary Disease [Internet]. Atlanta (GA): Centers for Disease Control and Prevention. What is COPD? 2018 June 6 [cited 2018 Nov 1]; [about 1 screen]. Available from: https://www.cdc.gov/copd/index.html
   Google Scholar
• Murphy SL, Xu JQ, Kochanek KD, Curtin SC, Arias E. Deaths: final data for 2015. Natl Vital Stat Rep. 2017:66(6):1–75.
   PubMedGoogle Scholar
• Ford ES, Murphy LB, Khaviou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45. doi:10.1378/chest.14-0972.
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245. doi:10.2147/CEOR.S34321.
   PubMedGoogle Scholar
• Blanchette CM, Gross NJ, Altman P. Rising costs of COPD and the potential for maintenance therapy to slow the trend. Am Health Drug Benefits. 2014;7(2):98–106.
   PubMedGoogle Scholar
• Han MK, Martinez CH, Au DH, et al. Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respir Med. 2016;4(6):473–526. doi:10.1016/S2213-2600(16)00094-1.
   PubMed Web of Science ®Google Scholar
• Petite SE. Characterization of chronic obstructive pulmonary disease prescribing patterns in the United States. Pulm Pharmacol Ther. 2018;49:119–122. doi:10.1016/j.pupt.2018.02.003.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD 2018 report [Internet]. GOLD; 2018. 142 p. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191. doi:10.7326/0003-4819-155-3-201108020-00008.
   PubMed Web of Science ®Google Scholar
• Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122(4):348–355. doi:10.1016/j.amjmed.2008.09.042.
   PubMed Web of Science ®Google Scholar
• Ford ES, Mannino DM, Giles WH, et al. Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010. COPD. 2014;11(3):247–255.
   PubMedGoogle Scholar
• Centers for Medicare and Medicaid Services (CMS). Chronic conditions among medicare beneficiaries, Chartbook, 2012 edition [Internet]. Baltimore (MD): CMS; 2012. p. 30. Available from: https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/chronic-conditions/downloads/2012chartbook.pdf
   Google Scholar
• Asche CV, Leader S, Plauschinat C, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2012;7:1–9. doi:10.2147/COPD.S25805.
   PubMed Web of Science ®Google Scholar
• Henry J. Kaiser Family Foundation. An overview of medicare. Issue Brief, February 2019. Available from: https://www.kff.org/medicare/issue-brief/an-overview-of-medicare/.
   Google Scholar
• Centers for Medicare and Medicaid Services. Dual eligible beneficiaries under medicare and medicaid. 2018. Available from: https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/Medicare_Beneficiaries_Dual_Eligibles_At_a_Glance.pdf
   Google Scholar
• Celli BR, Navaie M, Xu Z, et al. Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment. Int J Chron Obstruct Pulmon Dis. 2019;14:1019-1031. doi:10.2147/COPD.S199251.
   PubMed Web of Science ®Google Scholar
• Bishwakarma R, Zhang W, Kuo YF, et al. Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:477–486. doi:10.2147/COPD.S122354.
   PubMed Web of Science ®Google Scholar
• Qian J, Simoni-Wastila L, Rattinger GB, et al. Association between depression and maintenance medication adherence among Medicare beneficiaries with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2014;29(1):49–57. doi:10.1002/gps.3968.
   PubMed Web of Science ®Google Scholar
• Stuart BC, Simoni-Wastilla L, Zuckerman IH, et al. Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary disease. Am J Geriatr Pharmacother. 2010;8(5):441–453. doi:10.1016/j.amjopharm.2010.10.002.
   PubMedGoogle Scholar
• Nishi SPE, Maslonka M, Zhang W, et al. Pattern and adherence to maintenance medication use in Medicare beneficiaries with chronic obstructive pulmonary disease: 2008–2013. Chronic Obstr Pulm Dis. 2018;5(1):16–26. doi:10.15326/jcopdf.5.1.2017.0153.
   PubMed Web of Science ®Google Scholar
• Make B, Dutro MP, Paulose-Ram R, et al. Undertreatment of COPD: a retrospective analysis of us managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:201–209.
   PubMed Web of Science ®Google Scholar
• Carlin BW, Schuldheisz SK, Noth I, et al. Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care. Postgrad Med. 2017;129(7):725–733. doi:10.1080/00325481.2017.1353885.
   PubMed Web of Science ®Google Scholar
• Koehorst-ter HK, Movig K, van der Valk P, et al. The influence of type of inhalation device on adherence of COPD patients to inhaled medication. Expert Opin Drug Deliv. 2016;13(4):469–475. doi:10.1517/17425247.2016.1130695.
   PubMed Web of Science ®Google Scholar
• Darbà J, Ramírez G, Sicras A, et al. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Int Chronic Obstruct Pulmon Dis. 2015;10:2335–2345.
   PubMed Web of Science ®Google Scholar
• Braido F, Chrystyn H, Baiardini I, et al; Respiratory Effectiveness Group. "Trying, but failing" - the role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract. 2016;4(5):823–832. doi:10.1016/j.jaip.2016.03.002.
   PubMed Web of Science ®Google Scholar
• Barrons R, Wheeler J, Woods JA. Opportunities for inhaler device selection in elderly patients with asthma or COPD. Patient Intell. 2015;7:53–65.
   Google Scholar
• Melzer AC, Ghassemieh BJ, Gillespie SE, et al. Patient characteristics associated with poor inhaler technique among a cohort of patients with COPD. Respir Med. 2017;123:124–130. doi:10.1016/j.rmed.2016.12.011.
   PubMed Web of Science ®Google Scholar
• Chrystyn H, van der Palen J, Sharma R, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27(1):22. doi:10.1038/s41533-017-0016-z.
   PubMed Web of Science ®Google Scholar
• Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation technique errors with metered-dose inhalers among patients with obstructive lung diseases: a systematic review and meta-analysis of US studies. Chronic Obstr Pulm Dis. 2019;6(3): In press.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49:1601794. doi:10.1183/13993003.01794-2016.
   PubMed Web of Science ®Google Scholar
• Patel M, Steinberg K, Suarez-Barcelo M, et al. Chronic obstructive pulmonary disease in post-acute/long-term care settings: seizing opportunities to individualize teatment and device selection. J Am Med Dir Assoc. 2017;18(6):553.e17–553.e22. doi:10.1016/j.jamda.2017.03.020.
   Web of Science ®Google Scholar
• Kronick R, Gilmer TP, Dreyfus T, et al. CDPS-Medicare: the chronic illness and disability payment system modified to predict expenditures for Medicare beneficiaries [Internet]. Final Report to CMS; 2002. 147 p. Available from: http://cdps.ucsd.edu/CDPS_Medicare.pdf
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Centers for Medicare and Medicaid Services. Medicare chronic conditions prevalence state level: all beneficiaries by sex and age, 2007–2017 [Internet]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/CC_Main.html
   Google Scholar
• Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract. 2014;15:42. doi:10.1186/1471-2296-15-42.
   PubMed Web of Science ®Google Scholar
• Baker CL, Zou KH, Su J. Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data. Int J Chron Obstruct Pulmon Dis. 2014;9:431–439.
   PubMed Web of Science ®Google Scholar
• Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007;29(2):261–278. doi:10.1016/j.clinthera.2007.02.009.
   PubMed Web of Science ®Google Scholar
• Hanrahan JP, Hanania NA, Calhoun WJ, et al. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008;5(1):25–34. doi:10.1080/15412550701816187.
   PubMedGoogle Scholar
• Chen YJ, Makin C, Bollu VK, et al. Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists. J Med Econ. 2016;19(1):11–20. doi:10.3111/13696998.2015.1079530.
   PubMed Web of Science ®Google Scholar
• Foster JA, Yawn BP, Maziar A, et al. Enhancing COPD management in primary care settings. MedGenMed. 2007;9(3):24.
   PubMedGoogle Scholar
• Yawn BP, Wollan PC. Knowledge and attitudes of family physicians coming to COPD continuing medical education. Int J Chron Obstruct Pulmon Dis. 2008;3(2):311–318. doi:10.2147/COPD.S2486.
   PubMedGoogle Scholar
• Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: an expert panel consensus. Chronic Obstr Pul Dis. 2017;4(1):7–20. doi:10.15326/jcopdf.4.1.2016.0141.
   Web of Science ®Google Scholar
• Lane DC, Stemkowski S, Stanford RH, et al. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. Retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172. doi:10.18553/jmcp.2018.24.11.1165.
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Riley IL, Mannino DM. Defining and targeting health disparities in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2475–2496. doi:10.2147/COPD.S79077.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services (CMS) Office of Minority Health and RAND Corporation. Racial and ethnic disparities by gender in health care in Medicare advantage [Internet]. Baltimore (MD): CMS; 2017. 39 p. Available from: https://www.cms.gov/About-CMS/Agency-Information/OMH/Downloads/Health-Disparities-Racial-and-Ethnic-Disparities-by-Gender-National-Report.pdf
   Google Scholar
• Gandhi K, Lim E, Davis J, et al. Racial disparities in health service utilization among Medicare fee-for-service beneficiaries adjusting for multiple chronic conditions. J Aging Health. 2017;30(8):1224–1243. doi:10.1177/0898264317714143.
   PubMed Web of Science ®Google Scholar
• Siegel M ,Krishnan JA ,Lamson-Sullivan J, et al. Health disparities in chronic obstructive pulmonary disease. In: Gerald LB, Berry CE, editors. Health disparities in respiratory medicine. New York (NY): Springer; 2016. p. 189–206.
   Google Scholar
• D’Souza AO, Shah M, Dhamane AM, et al. Clinical and economic burden of COPD in a Medicaid population. COPD. 2014;11(2):212–220. doi:10.3109/15412555.2013.836168.
   PubMedGoogle Scholar
• Congressional Budget Office (CBO). Dual-eligible beneficiaries of Medicare and Medicaid: characteristics, health care spending, and evolving policies [Internet]. Washington (DC): CBO; 2013. 45 p. Available from: https://www.cbo.gov/sites/default/files/113th-congress-2013-2014/reports/44308dualeligibles2.pdf
   Google Scholar
• Jiang HJ, Wier LM, Potter DEB, et al. Potentially preventable hospitalizations among Medicare-Medicaid dual eligibles, 2008: statistical brief #96 [Internet]. Rockville (MD): Agency for Healthcare Quality and Research; 2010. 11 p. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb96.pdf
   Google Scholar
• Donohue JF, Ganapathy V, Bollu V, et al. Health status of patients with moderate to severe COPD after treatment with nebulized arformoterol tartrate or placebo for 1 year. Clin Ther. 2017;39(1):66–74. doi:10.1016/j.clinthera.2016.11.021.
   PubMed Web of Science ®Google Scholar
• The Medicare Payment Advisory Commission (MedPac). A data book: Health care spending and the Medicare program [Internet]. Washington (DC): MedPac; 2016. Section 4, Dual-eligible beneficiaries; p. 35–40. Available from: http://www.medpac.gov/docs/default-source/data-book/june-2016-data-book-section-4-dual-eligible-beneficiaries.pdf?sfvrsn=0
   Google Scholar
• Terasaki J, Nishi SPE, Ameredes BT, et al. Arformoterol: rationale for use in chronic obstructive pulmonary disease. Clin Invest. 2014;4(5):429–439. doi:10.4155/cli.14.32.
   Google Scholar
• Di Martino M, Agabiti N, Bauleo L, et al. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study. COPD. 2014;11(4):414–423. doi:10.3109/15412555.2013.839646.
   PubMedGoogle Scholar
• Singh G, Zhang W, Kuo YF, et al. Association of psychological disorders with 30-day readmission rates in patients with COPD. Chest. 2016;149(4):905–915. doi:10.1378/chest.15-0449.
   PubMed Web of Science ®Google Scholar
• Albrecht JS, Huang TY, Park Y, et al. New episodes of depression among Medicare beneficiaries with chronic obstructive pulmonary disease. Int J Geriatr Psychiatry. 2016;31(5):441–449. doi:10.1002/gps.4348.
   PubMed Web of Science ®Google Scholar
• Albrecht JS, Park Y, Hur P, et al. Adherence to maintenance medications among older adults with chronic obstructive pulmonary disease. The role of depression. Ann Am Thorac Soc. 2016;13(9):1497–1504. doi:10.1513/AnnalsATS.201602-136OC.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Wolf RA, Goodnight S, et al. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013;10(4):482–492. doi:10.3109/15412555.2013.773302.
   PubMedGoogle Scholar
• Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2011;68(13):1221–1232. doi:10.2146/ajhp100452.
   PubMed Web of Science ®Google Scholar
• Baird C, Lovell J, Johnson M, et al. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: a systematic review. Respir Med. 2017;129:130–139. doi:10.1016/j.rmed.2017.06.006.
   PubMed Web of Science ®Google Scholar
• Ding B, Small M, Scheffel G, et al. Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care. Int J Chron Obstruct Pulmon Dis. 2018;13:927–936. doi:10.2147/COPD.S154525.
   PubMed Web of Science ®Google Scholar
• Molimard M, Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2015;28(3):219–228. doi:10.1089/jamp.2014.1142.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Han MK, Allinson JP, et al. At the Root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1540–1551. doi:10.1164/rccm.201710-2028PP.
   PubMed Web of Science ®Google Scholar
• Rossi A, Butorac-Petanjek B, Chilosi M, et al. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies. Int J Chron Obstruct Pulmon Dis. 2017;12:2593–2610. doi:10.2147/COPD.S132236.
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli B. Natural history of COPD: gaps and opportunities. ERJ Open Res. 2017;3(4):00117-2017. doi:10.1183/23120541.00117-2017.
   PubMedGoogle Scholar
• Grossberg GT, Beck D, Zaidi SNY. Assessment in rapid depression geriatric patients. Clin Geriatr Med. 2017;33(3):383–391. doi:10.1016/j.cger.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Small GW. Differential diagnoses and assessment of depression in elderly patients. J Clin Psychiatry. 2009;70(12):e47. doi:10.4088/JCP.8001tx20c.
   PubMedGoogle Scholar
• Wells KB, Hays RD, Burnam MA, et al. Detection of depressive disorder for patients receiving prepaid or fee-for-service care. Results from the medical outcomes study. JAMA. 1989;262(23):3298–3302.
   PubMed Web of Science ®Google Scholar
• Shenolikar R, Bruno AS, Eaddy M, et al. Sensitivity of medication use to formulary controls in Medicare beneficiaries: a review of the literature. Am Health Drug Benefit. 2011;4(7):465–474.
   PubMedGoogle Scholar